| Company/Division name | Enzyvant |
| Parent company | Sumitomo Pharma |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Year reshoring implemented or to be implemented: | 2025 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Durham |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | regenerative medicines for rare diseas |
